Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.95 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | PPARG | P37231 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | FABP4 | P15090 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718113 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL1480333 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL29926444 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL8728913 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL7718095 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL29926968 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL29926582 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL1480331 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL1479340 | 1.00 | OXER1 (0.95) | OXER1LTB4R2MAPTALDH1A1ALOX5 | |
| SCHEMBL16670813 | 0.97 | OXER1 (1.00) | OXER1LTB4R2MAPTALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239889-A1 | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration | GOSSELIN JEAN | 2005-10-27 | — | — | US | claimed |
| US-20040132820-A1 | Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities | GOSSELIN JEAN (CA) | 2004-07-08 | — | — | US | claimed |
| US-6093741-A | ANTI-NEOPLASTIC AGENT IN THE PROPHYLAXIS AND TREATMENT OF CANCERS INDUCED BY TUMOR VIRUSES AND IN OTHER NEOPLASIC DISEASES | VIROCELL INC. (CA) | 2000-07-25 | — | — | US | claimed |
| JP-2000505435-A | — | — | 2000-05-09 | — | — | JP | claimed |
| EP-0881900-A1 | USE OF LEUKOTRIENE B 4? OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | Virocell Inc. (CA) | 1998-12-09 | — | — | EP | claimed |
| WO-1997029751-A1 | USE OF LEUKOTRIENE B4 OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | VIROCELL INC. (CA) | 1997-08-21 | — | — | WO | claimed |
| US-20150159115-A1 | PURIFICATION OF DPA ENRICHED OIL | OMEGA PROTEIN CORPORATION | 2015-06-11 | — | — | US | disclosed |
| US-20150133554-A1 | PURIFICATION OF DPA ENRICHED OIL | OMEGA PROTEIN CORPORATION | 2015-05-14 | — | — | US | disclosed |
| EP-2719382-A1 | Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-7914800-B2 | Immune response or immunopotentiation intensifier comprising leukotriene B4 | LTB4 SWEDEN AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7473708-B2 | Agents with leukotriene B4-like antiviral (enveloped RNA) activities | Gosselin, Jean (CA) | 2009-01-06 | — | — | US | disclosed |
| US-20060025479-A1 | Agents with leukotriene B4-like antiviral (enveloped RNA) activities | LTBE4 SWEDEN AB (SE) | 2006-02-02 | — | — | US | disclosed |
| US-20050239889-A1 | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration | GOSSELIN JEAN | 2005-10-27 | — | — | US | disclosed |
| US-20040208882-A1 | Ltb4 as vaccine adjuvant | LTB4 SWEDEN AB (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20040132820-A1 | Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities | GOSSELIN JEAN (CA) | 2004-07-08 | — | — | US | disclosed |
| US-6093741-A | ANTI-NEOPLASTIC AGENT IN THE PROPHYLAXIS AND TREATMENT OF CANCERS INDUCED BY TUMOR VIRUSES AND IN OTHER NEOPLASIC DISEASES | VIROCELL INC. (CA) | 2000-07-25 | — | — | US | disclosed |
| US-5789441-A | Leukotriene B4 as an antiviral and anti-neoplastic agent | VIROCELL INC. (CA) | 1998-08-04 | — | — | US | disclosed |